Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.

Trial Profile

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jun 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
    • 13 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 02 Jun 2017 Results (n=15) exploring changes in cerebrospinal fluid circulating tumor cells enumeration in response to treatment presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top